Mantopoulos T, Mitchell P, Welton N, McManus R, Andronis L. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results. European Journal of Health Economics 2015. In Press. DOI: 10.1007/s10198-015-0731-8
Andronis L. Analytic approaches for research priority-setting: issues, challenges and the way forward. Expert Review of Pharmacoeconomics and Outcomes Research 2015 Oct;15(5):745-54.
James N, Pirrie S, Pope A, Barton D, Andronis L et al. TRAPEZE: A randomised controlled trial of the clinical and cost effectiveness of chemotherapy with zoledronic acid, strontium-89 or both, in men with bony metastatic castrate refractory prostate cancer. Health Technology Assessment 2015. In press
Andronis L, Billingham, L, Bryan S, Barton P. A practical application of value of information and prospective payback of research to prioritise evaluative research. Medical Decision Making July 2015. pii: 0272989X15594369
James N, Andronis L, Goranitis I, Pirrie S, Pope A, Barton D et al. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. J Clin Oncol 33 (suppl; e16108), 2015
Thorn J, Coast J, Andronis L. Interpretation of the expected value of perfect information and research recommendations: a systematic review. Medical Decision Making May 2015. pii: 0272989X15586552
Brealey S, Andronis L, Dale V, Gibbon A, Gilbert F and Hendry M. The effect of waiting times from General Practitioner referral to Magnetic Resonance Imaging or orthopaedic consultation for the knee on patient-based outcomes. British Journal of Radiology. In press
Bryan S, Dormandy E, Roberts T, Ades A, Barton P, Juarez-Garcia A, Andronis L, Karnon J and Marteau T. Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. British Journal of General Practice 2011; 61(591):620-627
Barton P, Andronis L, Briggs A, McPherson K and Capewell S. Effectiveness and cost-effectiveness of cardiovascular disease prevention in whole populations: modelling study. British Medical Journal 2011 28: 343
Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, et al. (2010) A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technology Assessment; 14(50):1-103.
Brealey S, Andronis L, Dennis L, Atwell C, Bryan S, Coulton S, et al. (2010) Participants' preference for type of leaflet used to feed back the results of a randomised trial: a survey. Trials; 11:116.
Ashfaq K, Yahaya I , Hyde C, Andronis L, Barton P, Bayliss S, et al. (2010) Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technology Assessment; 14(54):iii-xi,
Bryan S, Andronis L, Hyde C, Connock M, Fry-Smith A, Wang D. (2010) Infliximab for the treatment of acute exacerbations of ulcerative colitis. Health Technology Assessment;14 Suppl 1:9-15.
Hyde C, Bryan S, Juarez-Garcia A, Andronis L, Fry-Smith A.(2009) Infliximab for the treatment of ulcerative colitis. Health Technology Assessment; 13 Suppl 3:7-11.
Andronis L, Barton P, Bryan S. (2009) Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technology Assessment; 13 (29):iii, ix-61.
DAMASK Trial Team (Andronis L, Atwell C, Brealey S, Bryan S, Collins S, Coulton S et al.) (2008) Effectiveness of GP access to MRI of the knee: a randomised trial. British Journal of General Practice; 58(556): e1-8
DAMASK Trial Team (Andronis L, Atwell C, Brealey S, Bryan S, Collins S, Coulton S et al.) (2008) Cost effectiveness of magnetic resonance imaging of the knee for patients presenting in primary care. British Journal of General Practice 58(556): e10-16